TABLE 1.

Clinical characteristics of reports with secukinumab from the FAERS database (January 2015 to September 2021).

Characteristics	Case number, n	Case proportion, %
Number of events	89,228
Gender
Female	50,251	56.32
Male	34,098	38.21
Unknown	4,879	5.47
Age (years)
<18	113	0.13
18≤ and ≤65	27,556	30.88
>65	5,539	6.21
Unknown	56,020	62.78
Indications (TOP five)
Psoriasis	35,870	40.20
Psoriatic arthropathy	16,991	19.04
Ankylosing spondylitis	6,474	7.26
Rheumatoid arthritis	401	0.45
Pustular psoriasis	158	0.18
Serious Outcome
Death	1,438	1.61
Life-threatening	693	0.78
Hospitalization	7,247	8.12
Disability	560	0.63
Congenital anomaly	22	0.02
Required intervention to prevent permanent impairment/damage	18	0.02
Other serious medical events	18,528	20.76
Reported Countries (Top five)
America	30,913	34.64
Canada	2,034	2.28
Britain	1,303	1.46
Germany	1,270	1.42
Japan	632	0.71
Reported Person
Health profession
Physician	12,918	14.48
Pharmacist	3,517	3.94
Other health professional	14,665	16.43
Non-healthcare professional
Consumer	55,809	62.55
Unknown	2,319	2.60
Reporting year
2021 Q3 a	15,358	17.21
2020	19,958	22.37
2019	17,834	19.99
2018	18,142	20.33
2017	10,097	11.32
2016	5,409	6.06
2015	2,430	2.72

^aThe third quarter of 2021.